ReviewChemistryOpen2026
Disarming the Hsp70-Bim Alliance: Small-Molecule and Peptidic Disruptors of a Chaperone-Apoptotic Switch in Cancer.
Review in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Heat-shock protein 70 (Hsp70) is a ubiquitous stress chaperone whose over-expression confers treatment resistance in many cancers. Recent structural and mechanistic work has uncovered an unexpected survival circuit: the proapoptotic BH3-only protein Bim binds a nucleotide-sensitive groove on the Hsp70 nucleotide-binding domain, sequestering itself from Bax/Bak while allosterically accelerating Hsp70's ATPase cycle and stabilizing oncogenic clients. This Hsp70-Bim protein-protein interaction (PPI) is enriched in tyrosine-kinase-inhibitor (TKI)-resistant chronic myeloid leukemia, endocrine-refractory breast cancer, glioblastoma, and other "chaperone-addicted" tumors, making it a selective vulnerability rather than a housekeeping liability. Early linear and stapled BH3 peptides proved the groove is drug-addressable but suffered from poor pharmacokinetics. A fragment-assisted screen then delivered a phenalene-dicarbonitrile chemotype, S1g-2, and optimized analogs that displace Bim with sub-micromolar potency, dismantle Hsp70-client hubs, and resensitize resistant xenografts to imatinib or tamoxifen without global proteostasis collapse. Orally bioavailable wedges thus convert a seemingly flat chaperone surface into an actionable checkpoint. This review integrates structural biology, assay technology, and medicinal chemistry to chart the rise of Hsp70-Bim inhibitors, evaluates combination strategies with BH3 mimetics, TKIs, and proteasome inhibitors, and highlights remaining challenges-cross-isoform breadth, species-relevant toxicology, biomarker-guided dosing, and potential impacts on antiviral immunity. Future directions include covalent or macrocyclic wedges, degrader hybrids, and adaptive pulse-dose regimens guided by proximity-ligation assays. Collectively, chemical disarming of the Hsp70-Bim alliance exemplifies how precision targeting of chaperone PPIs can recalibrate apoptotic thresholds and unlock new therapeutic space in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.